RESEARCH

Identifying individuals with undiagnosed post-traumatic stress disorder in a large United States civilian population – a machine learning approach

Patrick Gagnon-Sanschagrin1*, Jeff Schein2, Annette Urganus3, Elizabeth Serra1, Yawen Liang1, Primrose Musingarimi4, Martin Cloutier1, Annie Guérin1 and Lori L. Davis5,6

Abstract

Background: The proportion of patients with post-traumatic stress disorder (PTSD) that remain undiagnosed may be substantial. Without an accurate diagnosis, these patients may lack PTSD-targeted treatments and experience adverse health outcomes. This study used a machine learning approach to identify and describe civilian patients likely to have undiagnosed PTSD in the US commercial population.

Methods: The IBM® MarketScan® Commercial Subset (10/01/2015–12/31/2018) was used. A random forest machine learning model was developed and trained to differentiate between patients with and without PTSD using non–trauma-based features. The model was applied to patients for whom PTSD status could not be confirmed to identify individuals likely and unlikely to have undiagnosed PTSD. Patient characteristics, symptoms and complications potentially related to PTSD, treatments received, healthcare costs, and healthcare resource utilization were described separately for patients with PTSD (Actual Positive PTSD cohort), patients likely to have PTSD (Likely PTSD cohort), and patients without PTSD (Without PTSD cohort).

Results: A total of 44,342 patients were classified in the Actual Positive PTSD cohort, 5683 in the Likely PTSD cohort, and 2,074,471 in the Without PTSD cohort. While several symptoms/comorbidities were similar between the Actual Positive and Likely PTSD cohorts, others, including depression and anxiety disorders, suicidal thoughts/actions, and substance use, were more common in the Likely PTSD cohort, suggesting that certain symptoms may be exacerbated among those without a formal diagnosis. Mean per-patient-per-6-month healthcare costs were similar between the Actual Positive and Likely PTSD cohorts ($11,156 and $11,723) and were higher than those of the Without PTSD cohort ($3616); however, cost drivers differed between cohorts, with the Likely PTSD cohort experiencing more inpatient admissions and less outpatient visits than the Actual Positive PTSD cohort.

Conclusions: These findings suggest that the lack of a PTSD diagnosis and targeted management of PTSD may result in a greater burden among undiagnosed patients and highlights the need for increased awareness of PTSD in clinical practice and among the civilian population.

*Correspondence: patrick.gagnon-sanschagrin@analysisgroup.com
1 Analysis Group, Inc., 1190 avenue des Canadiens-de-Montréal, 1190 avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montréal, QC H3B 0G7, Canada
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Post-traumatic stress disorder (PTSD) is characterized by the presence of four clusters of symptoms that may present after experiencing or witnessing a traumatic event [1, 2]. These symptom clusters are associated with the traumatic event and include intrusive and recurrent memories, avoidance of trauma-related stimuli, negative mood or cognitions, and marked arousal and reactivity [1, 2]. The psychosocial impact of PTSD on patients is substantial, with increased risk of suicide attempts [3, 4], disability and unemployment [5], and comorbid conditions such as depression and substance use disorder [6–8]. In addition, PTSD is associated with a substantial economic burden to society, with a recent study estimating the burden at $232.2 billion in the United States (US) [9].

The 1-year prevalence of PTSD is estimated at 2.6 to 6.0% in civilians and 6.7 to 11.7% in military populations, and is twice as common among women compared to men [10]. Historically, PTSD has been predominantly studied among military individuals, likely due to the high prevalence of PTSD in this population [11, 12]. However, this represents a minority (14%) of the overall PTSD population in the US, with 86% of the PTSD population comprising civilians [9]. In addition, recent issues like COVID-19 [13], civil unrest [14], and climate change [15] continue to occur around the globe, adding to the growing concern of increased exposure to natural and societal traumatic events among civilians. Thus, additional research in this already underrecognized and understudied population is more imperative than ever.

In both military and civilian populations, PTSD is known to be undiagnosed [16], which may occur for multiple reasons, including patients being misdiagnosed with another mental health condition [6], patients not seeking help due to the stigma surrounding PTSD [16], patients’ lack of awareness of the condition/recognition of the symptoms [17], and patients’ lack of disclosure of traumatic history as this information is not routinely obtained by primary care physicians [18]. Indeed, studies have suggested that the proportion of patients with PTSD that remain undiagnosed may be substantial [6, 19–21], with one study reporting that only 11% of adult patients in primary care that met diagnostic criteria for PTSD had a recorded diagnosis of PTSD [6]. Without an accurate diagnosis, individuals may lack PTSD-targeted treatments, which may be associated with adverse outcomes like suicide attempts and overall poor quality of life, as well as a higher risk of sustained, long-term PTSD and depressive symptoms [16, 22, 23]. Accordingly, untreated individuals incur considerable care costs [23]. Notably, even among patients who are diagnosed with PTSD, many remain untreated [6, 16]. However, diagnosing PTSD is the first step towards proper and targeted management, since patients who receive a mental health diagnosis have more than 8-times higher odds of subsequently receiving mental health care [6].

Given the negative outcomes experienced by patients with untreated PTSD, undiagnosed PTSD is likely associated with a substantial clinical and economic burden as well. This suspected large burden warrants an improved method to identify these patients in real-world clinical practice, so that the impact of underdiagnosis and subsequently, undertreatment, on patients, their family, and society as a whole may be better understood. This is particularly important in the civilian population, where regular and systematic screening programs like those available for veterans are lacking [24].

Machine learning is an approach that has become increasingly used in the field of psychiatry in recent years to identify patients with a range of undiagnosed conditions from real-world, retrospective data sources [25–27]. Machine learning can be particularly useful when identifying undiagnosed patients with complex conditions such as PTSD, where a large number of characteristics and interactions must be considered and examined in the context of very heterogeneous populations and patient profiles [28]. Therefore, the current study implemented a machine learning approach to identify and describe commercially (i.e., privately) insured civilian adult patients likely to have undiagnosed PTSD in the US.

Methods
Data source
Data from the IBM® MarketScan® Commercial Subset (October 1, 2015 – December 31, 2018) were used. This database consists of employer- and health plan–sourced data containing medical and pharmacy claims data for beneficiaries, comprising employees, their spouses, and dependents who are covered by employer-sponsored private health insurance across all US census regions. The database includes records of inpatient (IP) services, IP admissions, outpatient (OP) services, prescription-drug claims, and other medical care. The database also includes standard demographic variables, such as age and gender; however, information on race is not available.
Because Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnoses are not available in claims data, International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes were used to identify symptoms and disorders based on clinical input.

Data are de-identified and comply with the requirements of the Health Insurance Portability and Accountability Act; therefore, no institutional review board approval was needed.

**Study design and sample selection**

The analyses for this study were conducted based on a retrospective cohort design to identify three (3) groups: Actual Positive PTSD, Likely PTSD, and Without PTSD cohorts. The study population included civilian, commercially insured adults (aged 18–64 years) in the US. Patients with diagnosed PTSD (Actual Positive PTSD cohort) were identified as those with \( \geq 2 \) PTSD diagnoses (ICD-10-CM: F43.1) on distinct dates and \( \geq 2 \) psychiatric evaluations within a 3-month period beginning on or before the first observed PTSD diagnosis. Patients confirmed to not have PTSD (Actual Negative PTSD cohort) were identified as those without any diagnosis of reaction to severe stress/adjustment disorder (ICD-10-CM: F43) at any time and with evidence that a diagnosis of reaction to severe stress/adjustment disorder was ruled out based on the presence of \( \geq 2 \) psychiatric evaluations within a 3-month period.

Patients likely or unlikely to have undiagnosed PTSD (Likely PTSD and Unlikely PTSD cohorts) were identified among patients for whom PTSD status could not be confirmed using available data (Unlabeled cohort). This cohort comprised patients without any diagnosis of reaction to severe stress/adjustment disorder and without evidence that a diagnosis of reaction to severe stress/adjustment disorder was ruled out. Patients likely or unlikely to have undiagnosed PTSD were defined based on model performance metrics, as described below. Patients unlikely to have undiagnosed PTSD and patients in the Actual Negative PTSD cohort comprised a representative sample of the general civilian population without PTSD (Without PTSD cohort); this population was expected to be highly underreported in claims data given that traumatic events that occurred before the start of data availability or that were not associated with healthcare resource use could not be captured. Therefore, indicators of trauma were not used as a main feature in the model; instead, the model was constructed using information that is routinely collected in clinical practice. Features included information on patients’ demographic characteristics, clinical characteristics, symptoms and complications potentially related to PTSD, treatments received, and use of emergency department (ED) services. Features were identified among the Actual Positive PTSD and Actual Negative PTSD cohorts on the index date (demographic characteristics) or during the study period (clinical characteristics, symptoms and complications potentially related to PTSD, treatments received, and use of ED services).

Both binary variables (i.e., presence of the feature) and count variables (i.e., number of days a claim for the feature was observed) were included in the model. For example, whether or not a specific treatment was received was captured as a binary variable, while the number of prescription fills for the treatment was captured as a count variable [34]. In total, 490 features were available for modeling (Additional file 1).

**Statistical analysis**

**Random forest model development**

A random forest machine learning model was developed and trained to differentiate between patients with and without PTSD using the Actual Positive PTSD and Actual Negative PTSD cohorts. A random forest model is a decision-tree based model, with each decision tree constructed based on a random sample of the data and a random selection of the features. This approach was chosen for its ability to model non-linear relationships between features and outcome variables and to accommodate large feature space [25]. The random forest model was implemented with a maximum of 200 trees, above which the model performance stabilized; default values of minimum node size (one), and depth of trees (indefinite) were selected. The most important features for the prediction of PTSD status were identified by the model; importance
was measured by permutation (i.e., the amount of prediction error added to the model if a feature is lost).

The final random forest model, after feature reduction [35], was trained based on 324 predictive features and was then applied to the Unlabeled cohort to identify individuals likely and unlikely to have undiagnosed PTSD (Additional file 1).

**Evaluation of model performance**

The performance of the random forest model was assessed using measures of area under the ROC curve [AUC] and F-beta scores. The AUC provides an aggregate measure of the performance of the model across all classification thresholds. Generally, the higher the AUC, the better the model performance; a model that randomly predicts patients’ probability of having PTSD would have an AUC of 0.5, while a model that predicts patients’ probability of having PTSD with 100% accuracy would have an AUC of 1.0.

F-beta scores are a measure of model performance that consist of the weighted (harmonic) mean of model precision and model recall at each potential classification threshold. The value of beta indicates the relative weights placed on precision and recall, such that beta = 1 indicates precision and recall are weighted equally and beta < 1 indicates that precision is weighted more heavily than recall. Similar to the AUC, a higher F-beta score generally indicates better model performance. As this study did not aim to identify all undiagnosed patients with PTSD, but rather to be confident that patients predicted to have undiagnosed PTSD may indeed have PTSD, multiple beta values that weighted precision more heavily than recall were assessed.

**Descriptive analysis of patient characteristics by PTSD status**

Patient characteristics, including demographic and clinical characteristics, symptoms and complications potentially related to PTSD, treatments received, healthcare costs, and healthcare resource utilization (HRU) were described separately for the Actual Positive PTSD, Likely PTSD, and Without PTSD cohorts. Demographic characteristics (e.g., age, sex) were described on the index date, while clinical characteristics (e.g., Charlson Comorbidity Index [CCI], comorbidities) were reported during the study period. Symptoms and complications potentially related to PTSD were described during the study period and included those of general health or quality of life (e.g., sleep disturbances); behavioral symptoms or disorders (e.g., eating disorders); symptoms involving cognition or perception (e.g., somnolence, stupor); physiological symptoms or reactions (e.g., abnormal blood pressure, abnormal heart rate); substance use indicators (e.g., rehabilitation services); and mental, behavioral, and neurodevelopmental disorders (e.g., major depressive disorder [MDD], anxiety disorders), among others. Treatments received by patients in the three cohorts were described during the study period. All-cause healthcare costs (2018 USD) and HRU incurred during the study period comprised medical (IP, OP, and ED) and pharmacy components, and were reported per-patient-per-6-months (PPP6M). Means, standard deviations, and medians were described for continuous variables, and frequency counts and percentages for categorical variables. No statistical comparisons between cohorts were conducted; all differences reported in this study are numerical.

**Results**

**Machine learning model performance**

The AUC of the model was 0.75, which indicated that the current model could distinguish between patients with and without PTSD reasonably well [36]. The F-beta score was maximized at a classification threshold of 80% when precision was weighted 10-times more than recall. Based on this threshold, patients with a predicted probability of having PTSD of at least 80% were classified as likely PTSD.

**Identification of cohorts**

A total of 2,124,496 patients were included in this study, of whom 44,342 (2.1%) were classified in the Actual Positive PTSD cohort, 35,021 (1.6%) were classified in the Actual Negative PTSD cohort, and 2,045,133 (96.3%) patients comprised the Unlabeled cohort. Among patients in the Unlabeled cohort, 5683 (0.3%) were identified by the machine learning algorithm as likely to have undiagnosed PTSD. The Without PTSD cohort included 2,074,471 patients in either the Actual Negative PTSD cohort or the Unlikely PTSD cohort. The top seven most important predictive features of PTSD identified by the machine learning algorithm were MDD, anxiety disorders, antiadrenergic medication use, bipolar disorder, musculoskeletal and connective tissue diseases, substance use/abuse, and physiological symptoms or reactions.

**Patient characteristics**

Patient characteristics were similar among patients with diagnosed PTSD and those likely to have undiagnosed PTSD, with a mean age of 38.7 years in the Actual Positive PTSD cohort and 38.2 years in the Likely PTSD cohort (Table 1). Additionally, 73.5% of the Actual Positive PTSD cohort and 69.4% of the Likely PTSD cohort were female.

Several symptoms and complications potentially related to PTSD were also similar between patients with
In contrast, other symptoms and complications were more common among patients likely to have undiagnosed PTSD than those with diagnosed PTSD, including sleep disturbances (18.4% in the Actual Positive PTSD cohort; 23.7% in the Likely PTSD cohort), suicidal thoughts or actions (5.1% in the Actual Positive PTSD cohort; 13.4% in the Likely PTSD cohort), and substance use (14.1% in the Actual Positive PTSD cohort; 29.2% in the Likely PTSD cohort), suggesting that certain symptoms may be exacerbated among those without a formal diagnosis.

Of note, comorbid mental health conditions were reported in over 50% of patients with diagnosed PTSD:

Table 1  Demographic and clinical characteristics

| Number of patients | Actual Positive PTSD cohort | Likely PTSD cohort | Without PTSD cohort |
|--------------------|-----------------------------|-------------------|--------------------|
| N = 44,342        |                             | N = 5683          | N = 2,074,471      |

Demographic characteristics

| Age, years; mean ± SD [median] | Actual Positive PTSD cohort | Likely PTSD cohort | Without PTSD cohort |
|-------------------------------|-----------------------------|-------------------|--------------------|
| 38.7 ± 13.0 [38.0]            |                             | 38.2 ± 12.6 [38.0] | 42.5 ± 13.1 [44.0] |

| Female, N (%)                 | Actual Positive PTSD cohort | Likely PTSD cohort | Without PTSD cohort |
|-------------------------------|-----------------------------|-------------------|--------------------|
| 32,579 (73.5%)                |                             | 3946 (69.4%)      | 1,464,405 (70.6%)  |

Health plan type, N (%)

| Preferred provider organization plan | Actual Positive PTSD cohort | Likely PTSD cohort | Without PTSD cohort |
|-------------------------------------|-----------------------------|-------------------|--------------------|
| 25,916 (58.4%)                      |                             | 3462 (60.9%)      | 1,203,878 (58.0%)  |

Health maintenance organization plan

| 5538 (12.5%)                      |                             | 656 (11.5%)       | 237,455 (11.4%)    |

Consumer-driven health plan

| 4463 (10.1%)                      |                             | 492 (8.7%)        | 193,161 (9.3%)     |

Non-capitated point-of-service plan

| 3229 (7.3%)                       |                             | 459 (8.1%)        | 180,090 (8.7%)     |

High deductible health plan

| 3003 (6.8%)                       |                             | 431 (7.6%)        | 184,075 (8.9%)     |

Comprehensive plan

| 1482 (3.3%)                      |                             | 99 (1.7%)         | 39,544 (1.9%)      |

Exclusive provider organization plan

| 315 (0.7%)                       |                             | 31 (0.5%)         | 15,225 (0.7%)      |

Capitated or partially capitated point-of-service plan

| 157 (0.4%)                       |                             | 19 (0.3%)         | 8399 (0.4%)        |

Unknown

| 239 (0.5%)                       |                             | 34 (0.6%)         | 12,644 (0.6%)      |

Census region of residence, N (%)

| South                           | Actual Positive PTSD cohort | Likely PTSD cohort | Without PTSD cohort |
|---------------------------------|-----------------------------|-------------------|--------------------|
| 16,210 (36.6%)                  |                             | 2284 (40.2%)      | 880,418 (42.4%)    |

Midwest/North Central

| 10,022 (22.6%)                  |                             | 1278 (22.5%)      | 420,312 (20.3%)    |

West

| 9151 (20.6%)                    |                             | 1232 (21.7%)      | 404,749 (19.5%)    |

Northeast

| 8872 (20.0%)                    |                             | 885 (15.6%)       | 367,195 (17.7%)    |

Unknown

| 87 (0.2%)                       |                             | 4 (0.1%)          | 1797 (0.1%)        |

Clinical characteristics

| CCI score, mean ± SD [median]    | Actual Positive PTSD cohort | Likely PTSD cohort | Without PTSD cohort |
|---------------------------------|-----------------------------|-------------------|--------------------|
| 0.3 ± 0.8 [0.0]                 |                             | 0.2 ± 0.6 [0.0]   | 0.2 ± 0.6 [0.0]    |

Most frequent diagnoses, N (%)

| General contact with health services | Actual Positive PTSD cohort | Likely PTSD cohort | Without PTSD cohort |
|-------------------------------------|-----------------------------|-------------------|--------------------|
| 29,450 (66.4%)                      |                             | 3777 (66.5%)      | 1,100,899 (53.1%)  |

Musculoskeletal and connective tissue diseases

| 19,420 (43.8%)                    |                             | 2480 (43.6%)      | 552,880 (26.7%)    |

General symptoms and abnormal findings

| 18,758 (42.3%)                    |                             | 2434 (42.8%)      | 566,973 (27.3%)    |

Endocrine, nutritional, and metabolic diseases

| 16,256 (36.7%)                    |                             | 2075 (36.5%)      | 565,530 (27.3%)    |

Respiratory diseases

| 14,361 (32.4%)                    |                             | 1642 (28.9%)      | 435,604 (21.0%)    |

Genitourinary diseases

| 12,162 (27.4%)                    |                             | 1445 (25.4%)      | 369,407 (17.8%)    |

Digestive system diseases

| 9500 (21.4%)                      |                             | 1181 (20.8%)      | 250,089 (12.1%)    |

Skin and subcutaneous tissue diseases

| 8980 (20.3%)                      |                             | 864 (15.2%)       | 306,338 (14.8%)    |

Injury

| 8817 (19.9%)                      |                             | 1148 (20.2%)      | 195,100 (9.4%)     |

Nervous system diseases

| 7553 (17.0%)                      |                             | 924 (16.3%)       | 130,672 (6.3%)     |

CCI Charlson Comorbidity Index, ICD-10-CM International Classification of Diseases, Tenth Revision, Clinical Modification, N Number, PTSD Post-traumatic stress disorder, SD Standard deviation

a Source: Quan, H., Li, B., Couris, C. H., Fushimi, K., Graham, P., Hider, P., Januel, J. M., & Sundararajan, V. (2011). Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. American Journal of Epidemiology, 173(6), 676–682

b Diagnoses were defined based on three-digit ICD-10-CM code categories. Diagnoses that may indicate a symptom or complication potentially related to PTSD have been excluded from this list and are reported in Fig. 2.
and over 60% of patients likely to have undiagnosed PTSD, with MDD (51.4% in the Actual Positive PTSD cohort; 69.7% in the Likely PTSD cohort) and anxiety disorders (50.9% in the Actual Positive PTSD cohort; 61.9% in the Likely PTSD cohort) among the most frequently observed mental health diagnoses. The frequency of these diagnoses among patients without PTSD was notably lower, with 4.4% of patients in the Without PTSD cohort having an observed diagnosis of MDD and 6.5% having an observed diagnosis of anxiety disorder.

Treatments received
Use of certain treatments was similar among patients with diagnosed PTSD and those likely to have undiagnosed PTSD, including selective serotonin reuptake inhibitors (SSRIs) indicated for PTSD, antianxiety
**Antidepressants**

| Treatment                                      | % of Cohort |
|-----------------------------------------------|-------------|
| SSRI approved for PTSD                        | 18.7%       |
| Other SSRIs                                   | 25.9%       |
| SNRIs                                         | 19.0%       |
| Tricyclic antidepressants                      | 4.6%        |
| Other antidepressants                         | 38.7%       |

**Anticonvulsants**

| Treatment                                      | % of Cohort |
|-----------------------------------------------|-------------|
| Benzodiazepines                               | 11.6%       |
| Valproic Acid                                 | 3.1%        |
| Other anticonvulsants                         | 23.5%       |

**Antianxiety agents, Antipsychotics, Antihypertensives**

| Treatment                                      | % of Cohort |
|-----------------------------------------------|-------------|
| Benzodiazepines                               | 22.0%       |
| Other antianxiety agents                      | 26.0%       |
| Atypical antipsychotics                       | 15.0%       |
| Conventional antipsychotics                   | 17.9%       |
| Antimanic agents                              | 28.2%       |

**Other frequent pharmacological treatments**

| Treatment                                      | % of Cohort |
|-----------------------------------------------|-------------|
| Opioid antagonists                            | 24.6%       |
| Antihistamines                                | 18.4%       |
| Non-narcotic agents                           | 15.3%       |
| Laxative drugs                                | 15.4%       |
| Musculoskeletal agents                        | 13.6%       |
| ADHD/ADHD antagonists                         | 12.5%       |
| Hypertensive/ sleep disorder agents           | 9.7%        |
| Migraine products                             | 4.7%        |
| Psychotropic agents                           | 3.3%        |

---

**Fig. 2** Treatments received¹ ADHD: Attention Deficit Hyperactivity Disorder; GPI: Generic Product Identifier; PTSD: post-traumatic stress disorder; SNRIs: serotonin and norepinephrine reuptake inhibitors; SSRIs: selective serotonin reuptake inhibitors. Note [1] Treatments received were reported based on the GPI classification system and observed pharmacy claims.
benzodiazepines, and anticonvulsant benzodiazepines (Fig. 2), which may suggest an overlap in the management of PTSD-related symptoms independent of diagnosis.

Conversely, the use of other treatments was more common among patients with likely undiagnosed PTSD than diagnosed PTSD, including atypical antipsychotics and antiadrenergics (Fig. 2).

### Healthcare costs and HRU

Mean all-cause total healthcare costs PPP6M were similar among patients with diagnosed PTSD ($11,156) and likely undiagnosed PTSD ($11,723), both of which were higher than the costs incurred by patients without PTSD ($3616). However, cost drivers differed between the two PTSD cohorts. Patients with likely undiagnosed PTSD incurred higher mean IP costs ($4452), but lower OP costs ($4638) than patients with diagnosed PTSD (IP: $2960; OP: $5616; Fig. 3).

Indeed, a higher proportion of patients with likely undiagnosed PTSD incurred ≥1 IP admission (22.5%) than those with diagnosed PTSD (12.0%), while patients with likely undiagnosed PTSD incurred fewer days with OP services (13.3 days) than those with diagnosed PTSD (18.3 days; Table 2).

### Discussion

Identifying patients with undiagnosed PTSD is particularly challenging given the complexity of the condition and variability in symptom presentation and disease course, which may also overlap with other mental health conditions [18, 37]. Additionally, in the context of real-world studies, claims data lack available information regarding patients’ history of trauma, which is a defining feature of PTSD. Despite these challenges, the current study used novel machine learning techniques to identify patients likely to have undiagnosed PTSD by leveraging information routinely collected in real-world

---

**Table 2** Healthcare resource utilization (PPP6M)

|                          | Actual Positive PTSD cohort | Likely PTSD cohort | Without PTSD cohort |
|--------------------------|-----------------------------|-------------------|---------------------|
| **N**                    | 44,342                      | 5683              | 2,074,471           |
| **Inpatient admissions, mean ± SD [median]** | 0.2 ± 0.6 [0.0] | 0.3 ± 0.7 [0.0] | 0.0 ± 0.2 [0.0] |
| ≥ 1 admission, N (%)     | 5305 (12.0%)                | 1278 (22.5%)       | 54,748 (2.6%)       |
| **Inpatient days, mean ± SD [median]** | 1.4 ± 6.2 [0.0] | 2.4 ± 6.8 [0.0] | 0.1 ± 1.5 [0.0] |
| **Days with emergency room services, mean ± SD [median]** | 0.6 ± 1.6 [0.0] | 0.7 ± 1.6 [0.0] | 0.2 ± 0.7 [0.0] |
| **Days with outpatient services, mean ± SD [median]** | 18.3 ± 14.2 [15.0] | 13.3 ± 13.5 [10.0] | 4.1 ± 6.4 [2.0] |

*N* Number, PPP6M Per patient per 6 months, PTSD Post-traumatic stress disorder, SD Standard deviation
clinical settings, including recorded symptoms, diagnoses, and treatments. The top predictive features of PTSD that were identified, including MDD, anxiety disorders, substance use/abuse, and musculoskeletal and connective tissue diseases, have previously been associated with PTSD in the literature as common comorbidities [38, 39], thus enforcing the predictive capabilities of the machine learning algorithm.

Among patients identified by the machine learning algorithm, many similar characteristics were observed between patients likely to have undiagnosed PTSD and patients with diagnosed PTSD, including established symptoms, several mental health complications, and associated conditions and medications. Taken together, the model performance, similarities between patients likely to have undiagnosed PTSD and patients with diagnosed PTSD, and differences compared to those without PTSD, seem to indicate that the patients identified with likely undiagnosed PTSD indeed have PTSD.

Some important differences were also observed between patients likely to have undiagnosed PTSD and patients with diagnosed PTSD. For instance, the frequency of MDD and anxiety disorders was higher among patients likely to have undiagnosed PTSD, which may suggest potential misdiagnosis or missing diagnostic coding for concurrent PTSD. In line with these findings, an electronic medical record-based study of primary care clinics in the US by Meltzer et al. found that almost half of patients with PTSD were misdiagnosed as having depression [6]. In the current study, patients likely to have undiagnosed PTSD were also observed to have increased rates of PTSD complications, including sleep disturbances, suicidal thoughts, and substance use. This finding suggests that symptoms may be exacerbated among those without a formal PTSD diagnosis, potentially due to management being directed primarily toward addressing individual symptoms. However, further research is warranted to confirm these results, given that patients with undiagnosed PTSD were identified via a machine learning algorithm, and thus some patients may have been incorrectly classified as having PTSD. Taken together, these findings suggest that the lack of a PTSD diagnosis and targeted management of PTSD may result in a greater complication and comorbidity burden in undiagnosed patients. This hypothesis is aligned with studies that have shown poor quality of life and risk of sustained, long-term PTSD and depressive symptoms among individuals with untreated PTSD, which can lead to substantial healthcare costs [22, 23]. While healthcare costs measured in the current study were similar between patients with diagnosed PTSD and those with likely undiagnosed PTSD, the long-term impact of untreated PTSD could eventually result in much higher lifetime costs.

The results of this study highlight the need for increased awareness of PTSD in clinical practice and among the civilian population. Improved mental health literacy and recognition of PTSD as a serious mental health condition may help to reduce the stigma and negative perceptions around PTSD and related trauma. In turn, this may potentially reduce existing barriers to seeking appropriate mental health services, which may facilitate formal diagnosis among the currently undiagnosed civilian population. As a step towards this goal, the results of the current study could potentially contribute to future research regarding the development of a simple, accessible clinical screening tool that relies primarily on routinely collected information, rather than the disclosure of trauma history, to identify patients in the US civilian population that may benefit from formal PTSD diagnostic evaluation. Such a tool that does not rely on the disclosure of trauma history may have the potential to identify a broader range of patients that could benefit from PTSD screening, including those for whom sensitive information regarding trauma history is not routinely collected or readily disclosed in a primary care setting [18].

In the military population, systematic screening initiatives, such as the one established by the Department of Defense and Veterans Health Administration, have contributed to timely diagnoses, clinically relevant reduction of symptoms, and remission of PTSD among treated Army service members [40]. Additionally, improved methods of PTSD screening could facilitate access to PTSD-targeted management and support programs, which are currently limited in the civilian population. For instance, rehabilitation programs like Individual Placement and Support (IPS) have been successful in returning Veterans with disabling PTSD back to steady employment with better incomes, in addition to improving quality of life for the recovering individual [41, 42]. Access to similar screening and rehabilitation strategies to identify undiagnosed civilian individuals with PTSD in a timely manner and provide much-needed support may help to alleviate the burden of the condition on patients, stakeholders, and society as a whole.

Limitations
The findings of this study should be considered in light of certain limitations. First, predictions made for the Unlabeled cohort could not be confirmed with the available data (i.e., it could not be clinically confirmed that patients predicted to have undiagnosed PTSD did in fact have PTSD). However, the classification threshold was selected to maximize model precision in order to increase confidence that patients included in the Likely PTSD cohort represented a subset of the civilian population with
undiagnosed PTSD. Importantly, further studies using different machine learning models are warranted to confirm the identification algorithm and the variations observed between the different cohorts. Second, traumatic events were not used as a main feature in the model due to underreporting in claims data. Third, given the nature of claims data, it was not possible to identify all clinical characteristics (e.g., subjectively experienced symptoms) associated with PTSD. In these cases, proxies for such characteristics were identified through discussions with a clinical expert, as feasible. As such, it is possible that some clinical characteristics may have been missed or misclassified. Fourth, while a primary objective of this study was to identify patients likely to have undiagnosed PTSD, further studies are warranted to assess the incremental impact of undiagnosis on clinical and economic outcomes related to PTSD. Fifth, because patients included in the Actual Negative PTSD cohort had ≥2 psychiatric evaluations within a 3-month period and were not a random selection of individuals without PTSD, included patients were likely different from the general population (e.g., they may have had more comorbidities). Sixth, patients in the Actual Positive PTSD cohort were required to have ≥2 psychiatric evaluations within a 3-month period, which may have selected for patients with more medical service use (e.g., with more severe PTSD). Finally, claims databases are subject to coding errors and inaccurate or missing data, but nevertheless remain a valuable source of information on a large sample of patients in a real-world setting.

Conclusion
These results highlight the importance of accurate and timely diagnosis of PTSD in order to potentially avoid complications associated with untreated PTSD that may result from non-targeted management of symptoms and lead to higher healthcare costs. Findings may have implications for the implementation of more accessible screening programs to aid in the identification of civilian patients that could benefit from early identification and treatment of PTSD.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12888-022-04267-6.

Acknowledgements
Medical writing support was provided by a professional medical writer, Christine Tam, an employee of Analysis Group, Inc.

Authors’ contributions
PGS, MC, ES, AG, and YL contributed to study conception and design, collection and assembly of data, and data analysis and interpretation. LLD, JS, AU, and PM contributed to study conception and design, data analysis and interpretation. All authors reviewed and approved the final content of this manuscript.

Funding
This study was funded by Otsuka Pharmaceutical Development & Commercialization, Inc. The study sponsor contributed to and approved the study design, participated in the interpretation of data, and reviewed and approved the manuscript; all authors contributed to the development of the manuscript and maintained control over the final content.

Availability of data and materials
The datasets generated and analyzed during the current study are not publicly available because they were used pursuant to a data use agreement. The data are available through requests made directly to IBM, via their website (https://www.ibm.com/products/marketscan-research-databases) or email (askibm@vnet.ibm.com).

Declarations

Ethics approval and consent to participate
Data used in this study are de-identified and comply with the requirements of the Health Insurance Portability and Accountability Act; therefore, no institutional review board approval was needed, per Title 45 of CFR, Part 46.101(b)(4) (https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/#46.101).

Consent for publication
Not applicable.

Competing interests
JS is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. AU is an employee of Lundbeck LLC. PM is an independent consultant and was an external consultant at Lundbeck A/S at the time the study was conducted. Otsuka Pharmaceutical Development & Commercialization, Inc. funded the development and conduct of this study and manuscript. PGS, MC, ES, and AG are employees of Analysis Group, Inc. YL was an employee of Analysis Group, Inc. at the time the study was conducted. Analysis Group, Inc. is a consulting company that has provided paid consulting services to Otsuka Pharmaceutical Development & Commercialization, Inc. LLD has received consulting fees from Boehringer Ingelheim, Janssen, Lundbeck, Otsuka, and Sgnant Health, and research funding or materials from Alkermes, Allergan, Aptinyx, Avanir, DoD, SAMHSA, Social Finance, Tonix, VA, and Westat.

Author details
1 Analysis Group, Inc., 1190 avenue des Canadiens-de-Montréal, 1190 avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montréal, QC H3B 0G7, Canada. 2 Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center, Princeton, NJ 08540, USA. 3 Lundbeck LLC, 6 Parkway North, Deerfield, IL 60015, USA. 4 H. Lundbeck A/S, Otsilliavej 9, Valby, Copenhagen, Denmark. 5 Research Service, Tuscaloosa Veterans Affairs Medical Center, 3701 Loop Rd East, Tuscaloosa, AL 35404, USA. 6 Department of Psychiatry and Behavioral Neurobiology, University of Alabama Heersink School of Medicine, 1720 7th Avenue South, Birmingham, AL 35233, USA.

Received: 6 December 2021 Accepted: 16 September 2022
Published online: 29 September 2022

References
1. American Psychological Association (APA). Clinical practice guideline for the treatment of PTSD. 2017.

Additional file 1. Features used in the development of the random forest model. The “Full list” tab includes all 490 features that were available for modeling. This full list is broken down by category in the “Trauma indicators”, “Symptoms and complications”, “Other diagnoses”, and “Medications” tabs, which provide a description of how each predictor was defined. The “Importance scores” tab includes the 324 predictive features that were used to train the final random forest model (with the corresponding importance scores).
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). 5th ed, 2013.

3. Kessler RC. Posttraumatic stress disorder: the burden to the individual and to society. J Clin Psychiatry. 2000;61(Suppl 5):4–12 discussion 3–4.

4. Milloyan B, Bulley A, Banderen-Roche K, Eaton WW, Goncalves-Bradley DC. Anxiety disorders and all-cause mortality: systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol. 2016;51(11):1467–75.

5. Zivin K, Bohnert AS, Mezuk B, Ilgen MA, Welsh D, Ratliff S, et al. Employment status of patients in the VA health system: implications for mental health services. Psychiatr Serv. 2011;62(11):35–8.

6. Meltzer EC, Averbuch T, Samet JH, Saitz R, Jabbar K, Lloyd-Travaglini C, et al. Discrepancy in diagnosis and treatment of post-traumatic stress disorder (PTSD): treatment for the wrong reason. J Behav Health Serv Res. 2012;39(2):190–201.

7. Seal KH, Cohen G, Waldrop A, Cohen BE, Maguen S, Ren L. Substance use disorders in Iraq and Afghanistan veterans in VA healthcare, 2001-2010: implications for screening, diagnosis and treatment. Drug Alcohol Depend. 2011;116(1–2):93–101.

8. Campbell DG, Felker BL, Liu CF, Yano EM, Kirchner JE, Chan D, et al. Prevalence of depression-PTSD comorbidity: implications for clinical practice guidelines and primary care-based interventions. J Gen Intern Med. 2007;22(6):711–8.

9. Davis L, Schein J, Cloutier M, Gagnon-Sanschagrin P, Matladn J, Urugans A. The economic burden of Post-traumatic stress disorder in the United States from a societal perspective. J Clin Psychiatry. 2022;83(3):211m14116.

10. Schein J, Houle C, Urugans A, Cloutier M, Patterson-Lomba O, Wang Y, et al. Prevalence of post-traumatic stress disorder in the United States: a systematic literature review. Curr Med Res Opin. 2021;37(12):2151–61.

11. Stein MB, Rothbaum BO. 175 years of Progress in PTSD therapeutics: learning from the past. Am J Psychiatry. 2018;175(6):508–16.

12. Lehavot K, Katon JW, Chau JW, Fortney JC, Simpson TL. Post-traumatic stress disorder by gender and veteran status. Am J Prev Med. 2018;54(1):e1–9.

13. Duthiel F, Mondillon L, Navel V. PTSD as the second tsunami of the SARS-Cov-2 pandemic. Psychol Med. 2021;51(10):1773–4.

14. Ni MY, Yao X, Leung KSM, Yau C, Leung CM, Lui P, et al. Depression and post-traumatic stress during major social unrest in Hong Kong: a 10-year prospective cohort study. Lancet. 2020;395(10220):273–84.

15. Padhy SK, Sarkar S, Panigrahi M, Paul S. Mental health effects of climate change. Indian J Occup Environ Med. 2015;19(1):13–7.

16. Wimalawansa S. Post-traumatic stress disorder (PTSD): treatment for the wrong reason. J Behav Health Serv Res. 2011;62(1):35–8.

17. Kantor V, Knefel M, Lueger-Schuster B. Perceived barriers and facilitators of the impact of IPS supported employment on PTSD-related occupational-psychosocial functional outcomes: results from a VA randomized-controlled trial. Psychiatr Rehabil J. 2018;41(2):246–56.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.